未找到相关数据
PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2-advanced breast cancer (BC): First results from the randomized, phase Ill BELLE-2 trial
被引：8
作者：
Baselga, J.
Im, S-A
Iwata, H.
Clemons, M.
Ito, Y.
Awada, A.
Chia, S.
Jagiello-Gruszfeld, A.
Pistilli, B.
Tseng, L-M
Hurvitz, S.
Masuda, N.
Cortes, J.
De Laurentiis, M.
Arteaga, C. L.
Jiang, Z.
Jonat, W.
Hachemi, S.
Le Mouhaer, S.
Di Tomaso, E.
Urban, P.
Massacesi, C.
Campone, M.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Seoul Natl Univ, Coll Med, Seoul, South Korea
[3] Aichi Canc Ctr, Nagoya, Aichi 464, Japan
[4] Ottawa Hosp, Res Inst, Ottawa, ON, Canada
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[6] Inst Jules Bordet, B-1000 Brussels, Belgium
[7] BC Canc Agcy, Vancouver, BC, Canada
[8] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[9] Inst Oncol MCMCC, Warsaw, Poland
[10] Osped Macerata, Macerata, Italy
[11] Taipei Vet Gen Hosp, Taipei, Taiwan
[12] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[13] Osaka Natl Hosp, Natl Hosp Org, Osaka, Japan
[14] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[15] Fdn G Pascale, Ist Nazl Tumori, Naples, Italy
[16] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[17] PLA, Beijing Hosp 307, Beijing, Peoples R China
[18] Univ Hosp Schleswig Holstein, Kiel, Germany
[19] Novartis Pharma SAS, Paris, France
[20] Novartis Inst BioMed Res, Cambridge, MA USA
[21] Novartis Pharma AG, Basel, Switzerland
[22] Rene Gauducheau Ctr Rech Cancerol, Inst Cancerol Ouest, Nantes, France
来源：
关键词：
D O I：
10.1158/1538-7445.SABCS15-S6-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S6-01
引用
收藏
页数：2
相关论文